Zacks Research Has Bearish Estimate for UTHR Q1 Earnings

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Stock analysts at Zacks Research lowered their Q1 2025 earnings estimates for United Therapeutics in a report issued on Monday, March 17th. Zacks Research analyst R. Department now anticipates that the biotechnology company will earn $6.36 per share for the quarter, down from their prior forecast of $6.93. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share. Zacks Research also issued estimates for United Therapeutics' Q2 2025 earnings at $6.71 EPS, Q3 2025 earnings at $6.95 EPS, Q4 2025 earnings at $6.68 EPS, FY2025 earnings at $26.69 EPS, Q1 2026 earnings at $6.48 EPS, Q2 2026 earnings at $6.76 EPS, Q3 2026 earnings at $7.12 EPS, Q4 2026 earnings at $7.36 EPS, FY2026 earnings at $27.73 EPS and FY2027 earnings at $28.24 EPS.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the prior year, the business posted $4.36 earnings per share.

Other analysts also recently issued reports about the stock. HC Wainwright reiterated a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. UBS Group lifted their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Finally, StockNews.com lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $388.25.

Remove Ads

United Therapeutics Stock Performance

Shares of United Therapeutics stock traded down $0.61 on Wednesday, hitting $312.99. 1,155,261 shares of the company traded hands, compared to its average volume of 446,848. United Therapeutics has a 52 week low of $221.53 and a 52 week high of $417.82. The business has a 50-day simple moving average of $345.10 and a 200 day simple moving average of $357.02. The stock has a market capitalization of $14.06 billion, a P/E ratio of 13.75, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Milestone Asset Management LLC boosted its position in United Therapeutics by 56.5% in the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company's stock valued at $1,014,000 after buying an additional 1,037 shares during the period. Janney Montgomery Scott LLC boosted its position in United Therapeutics by 9.1% in the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company's stock valued at $3,326,000 after buying an additional 789 shares during the period. JPMorgan Chase & Co. boosted its position in United Therapeutics by 35.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company's stock valued at $68,999,000 after buying an additional 50,291 shares during the period. Burney Co. lifted its stake in United Therapeutics by 113.3% in the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company's stock worth $8,441,000 after acquiring an additional 12,705 shares during the period. Finally, Franklin Resources Inc. lifted its stake in United Therapeutics by 97.7% in the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company's stock worth $89,532,000 after acquiring an additional 123,929 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of the business's stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the transaction, the director now owns 5,528 shares in the company, valued at $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at $896,950.62. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 90,255 shares of company stock worth $32,614,521. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.